United Health Accuses Celgene of Monopolizing Thalomid, Revlimid

United HealthCare Services Inc. sued Celgene Corp. in Minnesota federal court over an alleged scheme to monopolize two drugs, about eight months after Celgene paid $55 million to settle a failed class action that made similar claims.

“Celgene constructed an impenetrable monopolistic fortress and engaged in a multi-pronged scheme to unlawfully maintain 100% share of the market for these two drugs, and massively inflate its profits,” the antitrust lawsuit says.

It accuses Celgene, a Bristol-Myers Squibb Co. subsidiary, of using an array of anti-competitive tactics to corner the market for Thalomid, a leprosy medication, and Revlimid, a related drug that ...